This target trial emulation examined whether adding semaglutide or tirzepatide to existing IBD therapy improves 1-year clinical outcomes in stable IBD patients with comorbid obesity and/or diabetes, using U.S. claims data (OptumLabs, 2018–2023) across two cohorts: those on 5-ASA/no IBD therapy (cohort 1, n=4,056 matched pairs) and those on advanced therapies/immunomodulators (cohort 2, n=692 matched pairs).
GLP-1RA initiation did not reduce 1-year IBD relapse risk in either cohort. In cohort 1, relapse rates were identical (7.9% vs. 7.9%; RR 1.01, 95% CI 0.82–1.24). In cohort 2, there was a non-significant trend toward lower relapse (12.4% vs. 15.6%; RR 0.80, 95% CI 0.55–1.15). Safety outcomes were similar in both groups. Roughly one-third of patients discontinued GLP-1RAs within 1 year.
- Observational claims data cannot confirm actual medication use or adherence; ~33–36% discontinued GLP-1RAs within 1 year, which may dilute any true effect. - Relapse defined by administrative codes (hospitalization, surgery, prednisone use) may not capture endoscopic or biomarker-based disease activity. - Cohort 2 was relatively small (n=346 per arm), leaving the study underpowered to detect modest treatment effects (CI spans 0.55–1.15).
Clinicians can reassure stable IBD patients that starting semaglutide or tirzepatide for obesity or diabetes does not appear to worsen disease control. However, GLP-1RAs should not yet be prescribed with the expectation of improving IBD outcomes, as no benefit was demonstrated.
Explore related topics
